US Patent

US8779187 — Soft-gelatin capsule formulation

Formulation · Assigned to Sumcampo AG · Expires 2027-01-23 · 1y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which improves the compound's stability.

USPTO Abstract

The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.

Drugs covered by this patent

Patent Metadata

Patent number
US8779187
Jurisdiction
US
Classification
Formulation
Expires
2027-01-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Sumcampo AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.